The effect of vehicles on spray drying of rifampicin inhalable microparticles: In vitro and in vivo evaluation

Daru

Volumn 16, Issue 3, 2008, Pages 128-135

  Darbandi, M A ^a   Rouholamini, Najafabadi A ^a,c   Gilani, K ^a   Tajerzadeh, H ^b  

^a Aerosol Research Laboratory   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Aerodynamic behaviour; Dry powder inhaler; Pulmonary absorption; Rifampicin

Indexed keywords

DICHLOROMETHANE; DRUG VEHICLE; HELIUM; RIFAMPICIN; WATER;

AEROSOL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; DENSITOMETRY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; LASER DIFFRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEMBRANE MICROPARTICLE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RAT; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; SOLUTION AND SOLUBILITY; SPRAY DRYING; TEMPERATURE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 50949094945     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Zeng X.M, Martin GP, Marriot C. The controlled delivery of drugs to the lung. Int. J. pharm. 1995; 124: 149-164.
2. Byron PR. Prediction of drug residence times in regions of the human respiratory tracts following aerosols inhalation. J. Pharm. Sci. 1986; 75: 433-438.
3. Le Brun P.P.H, De Boer AH, Gjaltama D, Hagedoorn P, Heijerman HGM, Frijlink HW. Inhalation of tobramycin in cystic fibrosis part2: optimization of tobramycin solution for a jet and ultrasonic nebulizer. Int. J. Pharm. 1999;189: 215-225.
4. Diot P, Dequin P.F, Rivoire B, Gagnadoux F, Faurisson F, Diot E, Boissinot E, Le pape A, Palmer L, Lemarie E. Aerosoles and anti infectious agents. J. Aerosol. Med. 2001; 14: 55-64.
5. Le Brun P.P.H, De Boer AH, Gjaltama D, Heijerman HGM. A review of the technical aspects of drug nebulization. Pharm. World. Sci. 2000; 22: 75-81.
6. De Boer AH, Le Brun P.P.H, Vanderwoude HG, Hagedoorn P, Heijerman H.G.M, Frijlink HW. Dry powder inhalation of antibiotics in cystic fibrosis therapy part1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principal. Europ.J. Pharm. Biopharm. 2002; 54: 17-24.
7. Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlucast hydrate. Int. J. Pharm. 1998; 172: 178-188.
8. Gupta P, Bansal AK. Spray drying for generation of a ternary amorphous system of celecoxib, PVP and meglomine. Pharm. Dev.Technol. 2005; 10: 273-281.
9. Jalalipour M, Gilani K, Tajerzadeh H, Najafabadi A.R, Barghi M. Characterirization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents. Int. J. Pharm. 2008; 352: 209-216.
10. Gilani K, Najafabadi A.R, Barghi M, Rafiee-Tehrani M. Aerosolisation of beclomethasone dipropionate using spray dried lactose/polyethylene glycol carriers. Eur. J. Pharm. Biopharm. 2004; 58: 595-606.
11. Najafabadi A.R, Gilani K, Barghi M, Rafiee-Tehrani M. The effect of vehicle on physical properties and aerosolisation behaviors of disodium cromoglycate microparticles spray dried alone or with L-leucine. Int. J. Pharm. 2004; 285: 97-108.
12. Gilani K, Najafabadi A.R, Barghi M, The effect of water to ethanol feed ratio on physical properties and aerosolization behavior of spray dried cromolyn sodium particles. J. Pharm. Sci. 2005; 94: 1048-1059.
13. Darbandi M, Gilani K, Najafabadi A.R, Barghi M, Tajerzadeh H. The effect of spray drying solvent on in vitro deposition profiles and pulmonary absorption of rifampicin microparticles. Drug. Deliv. Sci. Tech. 2008; 18:203-208.
14. Najafabadi A.R, Asgharian R, Tajerzadeh H, Gilani K, Vatanara A, Darabi M. The effect of fine lactose as a third component on aerosolization of cefotaxime sodium from dry powder formulations.DARU.2006; 14:155-163.
15. Saito H, Tomioka H. Therapeutic Efficacy of liposome-entrapped rifampin against mycobacterium avium complex infection induced in mice. Antimicrobial. Agent. Chemoter. 1989; 33: 429-433.
16. Zeng X.M, Martin GP, Marriott C, Pritchard J. Lactose as a carrier in dry powder formulations: The influence of surface characteristics on drug delivery. J. Pharm. Sci. 2001; 90: 1424-1434.
17. Enna SJ, Schanker, L.S. Absorption of saccharides and urea from the rat lung. Am. J. Physiol. 1972; 222:409-414.
18. Yamamoto A, Yamada K, Muramatsu H, Nishinaka A, Okumura S, Okada N, Fujita T, Muranishi S. Control of pulmonary absorption of water-soluble compounds by various viscous vehicles. Int. J. Pharm 2004; 282: 141-149.
19. Iida K, Otsuka A, Danjo K, Sunada H. Measurement of adhesive force between particles and polymer-filme. Chem. Pharm. bull. 1992; 40: 189-192.
20. Nicklin P.L, Bayley D, Giddlings J, Craig S.J, Cummins L.L, Hastwell J.G, Philips J.A. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP-64128A): Comparison with other delivery routs. Pharm. Res.1998; 15: 583-591.
21. Ogura T, Furuya Y, Matsuura S. HPMC capsule an alternative to gelatin. Pharm. Technol. Eur. 1998; 10: 32-42.
22. Kassem N.M, Shamat M.A, Duval C. The inspirable properties of a carrier- free dry powder aerosol formulation. J. Pharm. Pharmacol. 1991; 43, 75p.